Ms. Lee et al., HEPATITIS-B VACCINATION AND REDUCED RISK OF PRIMARY LIVER-CANCER AMONG MALE-ADULTS - A COHORT STUDY IN KOREA, International journal of epidemiology, 27(2), 1998, pp. 316-319
Background Primary liver cancer is an important health problem in Kore
a, where hepatitis B virus (HBV) infection is prevalent. The authors c
onducted a prospective cohort study to evaluate the protective effect
of HBV vaccination against liver cancer in adults. Methods A total of
370 285 males aged greater than or equal to 30 comprised the study pop
ulation. They were clinically free of liver diseases, and had not been
vaccinated against HBV at enrolment. The results of HBV surface antig
en (HBsAg) and antibody to HBsAg (antiHBs) marker positivity and those
of the vaccination programme which took place during 1985 were used f
or the construction of the cohort. About 5% (n = 18 914) were HBsAg po
sitive, 78 094 were anti-HBs positive, and 273 277 were negative for b
oth. Among the candidates for HBV vaccination (n = 273 277), 35 934 (1
3.2%) people had been vaccinated against HBV during 1985. Cases of liv
er cancer were ascertained by record linkage and from medical records
covering 1986-1989. A multivariate log-linear model was used to rest s
tatistical significance and to estimate relative risks (RR). Results T
he total follow-up period was 1 404 566 person-years, with an average
of 3 years and 10 months. A total of 302 incident cases were ascertain
ed. The overall incidence rate of liver cancer was 21.7 per 100 000 pe
rson-years. With reference to the incidence level among the unvaccinat
ed and uninfected the RR of primary liver cancer among the chronically
infected and that of the unvaccinated and infected was 18.1 (95% CI:
14.2-22.9) and 0.34 (95% CI : 0.19-0.60), respectively. The RR among t
he vaccinated group was 0.58 (95% CI : 0.31-1.09). Conclusions This st
udy suggested that artificial immunization through HBV vaccination, ev
en in adulthood, reduces the risk of liver cancer. It might also offer
a practicable means of primary prevention, especially in areas with h
yperendemicity of HBV infection.